Alanosine - CAS 5854-93-3
Category: Inhibitor
Please be kindly noted products are not for therapeutic use. We do not sell to patients.
Molecular Formula:
C3H7N3O4
Molecular Weight:
149.11
COA:
Inquire
Targets:
Antibacterial
Description:
Alanosine, also known as L-alanosine, is an antitumor antibiotic substance from the fermentation of Streptomyces alanosinicus. L-Alanosine inhibits adenylosuccinate synthetase to disrupt de novo purine biosynthesis, inhibiting cellular metabolism in MTAP-deficient tumor cells.
Appearance:
Solid powder
Synonyms:
(S)-2-amino-3-(hydroxy(nitroso)amino)propanoic acid; SDX102; SDX-102; SDX 102; alanosine; L-alanosine.
Storage:
Store in a cool and dry place (or refer to the Certificate of Analysis).
MSDS:
Inquire
Boiling Point:
366.9±52.0 °C at 760 Torr
Melting Point:
184-187 °C (decomp)
Density:
1.81±0.1 g/cm3
InChIKey:
MLFKVJCWGUZWNV-REOHCLBHSA-N
InChI:
1S/C3H7N3O4/c4-2(3(7)8)1-6(10)5-9/h2,10H,1,4H2,(H,7,8)/t2-/m0/s1
Canonical SMILES:
O=C(O)[C@@H](N)CN(O)N=O
1.Gateways to clinical trials.
Tomillero A, Moral MA. Methods Find Exp Clin Pharmacol. 2009 Sep;31(7):463-93.
Gateways to Clinical Trials is a guide to the most recent clinical trials in current literature and congresses. The data in the following tables has been retrieved from the Clinical Trials Knowledge Area of Prous Science Integrity, the drug discovery and development portal, http://integrity.prous.com. This issue focuses on the following selection of drugs: AAV1/SERCA2a, Abacavir sulfate/lamivudine, Adalimumab, Aliskiren fumarate, Ambrisentan, Aripiprazole, AT-7519, Atazanavir sulfate, Atomoxetine hydrochloride, Azacitidine, Azelnidipine; Besifloxacin hydrochloride, Bevacizumab, Bioabsorbable everolimus-eluting coronary stent, Bortezomib, Bosentan, Budesonide/formoterol fumarate; CAIV-T, Carisbamate, Casopitant mesylate, Certolizumab pegol, Cetuximab, Ciclesonide, Ciprofloxacin/dexamethasone, CTCE-9908; Dalcetrapib, Darunavir, Deferasirox, Desloratadine, Disitertide, Drotrecogin alfa (activated), DTA-H19, Duloxetine hydrochloride, Dutasteride; Ecogramostim, Efalizumab, Emtricitabine, Eribulin mesilate, Escitalopram oxalate, Eszopiclone, EUR-1008, Everolimus-eluting coronary stent, Exenatide; Fampridine, Fluticasone furoate, Formoterol fumarate/fluticasone propionate, Fosamprenavir calcium, Fulvestrant; Gabapentin enacarbil, GS-7904L; HPV-6/11/16/18, Human Secretin, Hydralazine hydrochloride/isosorbide dinitrate; Imatinib mesylate, Imexon, Inalimarev/Falimarev, Indacaterol, Indacaterol maleate, Inhalable human insulin, Insulin detemir, Insulin glargine, Ixabepilone; L-Alanosine, Lapatinib ditosylate, Lenalidomide, Levocetirizine dihydrochloride, Liraglutide, Lisdexamfetamine mesilate, Lopinavir, Loratadine/montelukast sodium, Lutropin alfa; MeNZB, Mepolizumab, Micafungin sodium, Morphine hydrochloride; Nabiximols, Nikkomycin Z; Olmesartan medoxomil, Omalizumab; Paclitaxel-eluting stent, Pegfilgrastim, Peginterferon alfa-2a, Peginterferon alfa-2b, Perifosine, PF-489791, Plitidepsin, Posaconazole, Pregabalin; QAX-576; Raltegravir potassium, Ramelteon, Rasagiline mesilate, Recombinant human relaxin H2, rhGAD65, Rivaroxaban, Rosuvastatin calcium, Rotigotine; Saxagliptin, SCH-530348, Sirolimus-eluting stent, SLIT-amikacin, Sorafenib, Sotrastaurin, SR-16234, Sulforaphane; Tadalafil, Tanespimycin, Tapentadol hydrochloride, Teriparatide, Tesofensine, Tiotropium bromide, Tipifarnib, Tirapazamine, TMC-207, Tocilizumab, Tolvaptan, Tosedostat, Treprostinil sodium; Ustekinumab; Varespladib methyl, Vicriviroc, Vildagliptin, Vildagliptin/metformin hydrochloride, Volociximab, Voriconazole; Ziconotide, Ziprasidone hydrochloride.
2.Effects of adenosine monophosphate-activated kinase activators on bovine oocyte nuclear maturation in vitro.
Bilodeau-Goeseels S1, Sasseville M, Guillemette C, Richard FJ. Mol Reprod Dev. 2007 Aug;74(8):1021-34.
The purpose of this study was to examine the effects of an activator of AMPK (5-aminoimidazole-4-carboxamide 1-beta-D-ribofuranoside (AICAR)) on bovine oocyte nuclear maturation in vitro. After 7 hr of culture, AICAR (1 mM) significantly increased the percentages of cumulus-enclosed oocytes (CEO) and denuded oocytes (DO) remaining at the germinal vesicle stage. After 22 hr of culture, AICAR significantly reduced the percentage of CEO reaching metaphase II (MII). AICAR at 1.0 mM also increased the inhibitory effect of the adenylate cyclase activator forskolin in CEO; however, at 0.05 mM, AICAR increased the percentage of oocytes at MII after 22 hr of culture compared to forskolin alone. The adenosine kinase inhibitor 5'-aminodeoxyadenosine reversed the effect of AICAR in CEO and DO showing that phosphorylation of AICAR by adenosine kinase is required for its inhibitory activity. GMP, but not AMP, inhibited meiosis in CEO and DO; however, inhibition of guanyl and adenyl nucleotides synthesis did not reverse the effect of AICAR suggesting that the inhibitory effect of AICAR is not due to increased synthesis of these nucleotides.
3.Lack of methylthioadenosine phosphorylase expression in mantle cell lymphoma is associated with shorter survival: implications for a potential targeted therapy.
Marcé S1, Balagué O, Colomo L, Martinez A, Höller S, Villamor N, Bosch F, Ott G, Rosenwald A, Leoni L, Esteller M, Fraga MF, Montserrat E, Colomer D, Campo E. Clin Cancer Res. 2006 Jun 15;12(12):3754-61.
PURPOSE: To determine the methylthioadenosine phosphorylase (MTAP) gene alterations in mantle cell lymphoma (MCL) and to investigate whether the targeted inactivation of the alternative de novo AMP synthesis pathway may be a useful therapeutic strategy in tumors with inactivation of this enzyme.
4.Genome-scale analysis of anti-metabolite directed strain engineering.
Bonomo J1, Lynch MD, Warnecke T, Price JV, Gill RT. Metab Eng. 2008 Mar;10(2):109-20. Epub 2007 Nov 5.
Classic strain engineering methods have previously been limited by the low-throughput of conventional sequencing technology. Here, we applied a new genomics technology, scalar analysis of library enrichments (SCALEs), to measure >3 million Escherichia coli genomic library clone enrichment patterns resulting from growth selections employing three aspartic-acid anti-metabolites. Our objective was to assess the extent to which access to genome-scale enrichment patterns would provide strain-engineering insights not reasonably accessible through the use of conventional sequencing. We determined that the SCALEs method identified a surprisingly large range of anti-metabolite tolerance regions (423, 865, or 909 regions for each of the three anti-metabolites) when compared to the number of regions (1-3 regions) indicated by conventional sequencing. Genome-scale methods uniquely enable the calculation of clone fitness values by providing concentration data for all clones within a genomic library before and after a period of selection.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related Antibacterial Products


CAS 144-83-2 Sulfapyridine

Sulfapyridine
(CAS: 144-83-2)

Sulfapyridine is a sulfonamide antibacterial.

CAS 116-43-8 Succinylsulfathiazole

Succinylsulfathiazole
(CAS: 116-43-8)

Succinylsulfathiazole, a sulfonamide derivative, could restrain the bacteria in the intestine to block the production of folic acid.

CAS 5490-27-7 Dihydrostreptomycin sesquisulfate

Dihydrostreptomycin sesquisulfate
(CAS: 5490-27-7)

Dihydrostreptomycin sesquisulfate is a derivative of Streptomycin used to treat bacterial diseases in cattle, pigs and sheep.

LY 215890
(CAS: 153502-35-3)

LY 215890 has been found to have probable antibiotic activity.

CAS 32887-01-7 Mecillinam

Mecillinam
(CAS: 32887-01-7)

Mecillinam is an extended-spectrum penicillin antibiotic as an active antibacterial against gram-negative bacteria.

CAS 10592-13-9 Doxycycline HCl

Doxycycline HCl
(CAS: 10592-13-9)

Doxycycline HCl is a tetracycline antibiotic that commonly used to treat a variety of infections and MMP inhibitor.

ABT-255
(CAS: 186293-38-9)

ABT-255, a novel 2-pyridone antibacterial agent, is an analog of ABT-719 with improvements in the therapeutic margin against common gram-positive and -negative ...

CAS 97519-39-6 Ceftibuten

Ceftibuten
(CAS: 97519-39-6)

Ceftibuten is a third-generation cephalosporin antibiotic. It displayed high activity against Haemophilus influenzae and Branhamella catarrhalis. It is an orall...

Chemical Structure

CAS 5854-93-3 Alanosine

Quick Inquiry

Verification code

Featured Items